Generic Name:
axicabtagene ciloleucel
Project Status:
Pending
Therapeutic Area:
Relapsed or refractory follicular lymphoma
Manufacturer:
Gilead Sciences Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Yescarta
Project Line:
Reimbursement Review
Project Number:
PG0314-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma
Details
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) after two or more lines of systemic therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) after two or more lines of systemic therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.